Insider Trading Case Refuels E&C GOP's Concern About FDA Protection Of Trade Secrets

House Energy & Commerce leaders are raising new concerns about FDA's ability to protect trade secrets and confidential information after federal officials in New York recently charged a political intelligence consultant and former FDA official with obtaining the status of a generic drug and illegally providing the information to a portfolio manager. E&C Chair Fred Upton (R-MI) and health subcommittee Chair Joseph Pitts (R-PA) first wrote to FDA in February questioning the adequacy of the agency’s procedures to protect the...